Last reviewed · How we verify
estrace cream (Reference)
At a glance
| Generic name | estrace cream (Reference) |
|---|---|
| Also known as | Reference Listed Drug product |
| Sponsor | Padagis LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy (PHASE3)
- Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women. (PHASE1)
- A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis (PHASE3)
- Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- estrace cream (Reference) CI brief — competitive landscape report
- estrace cream (Reference) updates RSS · CI watch RSS
- Padagis LLC portfolio CI